U.S. FDA Will Give Takeda's Alogliptin A Second Chance With New Study Design
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical will make a fresh stab at obtaining U.S. FDA approval for alogliptin, a selective dipeptidyl peptidase IV inhibitor for type 2 diabetes, after receiving a FDA nod for the study design of a cardiovascular outcomes trial, the company said